Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD109 vs Components in Obstructive Sleep Apnea
NCT04580394Phase 2Completed
- Sponsor
- Apnimed, Inc.
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AD109 in obstructive sleep apnea (OSA) (4 arms), sponsored by Apnimed, Inc. Primary endpoint: Change in Hypoxic Burden. Started Oct 2020; status: completed.
02
Drugs
AD109
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04580394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580394.